Liquid biopsies in lung cancer—time to implement research technologies in routine care?

Kohn, Linda M.; Johansson, Mikael; Grankvist, Kjell; Nilsson, Jonas

doi:10.21037/atm.2017.04.12

Cited by 27 publications

(22 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First‐generation sequencing (also known as Sanger sequencing or direct sequencing (DS)), next‐generation sequencing (NGS), and real‐time quantitative polymerase chain reaction (qPCR)‐based assay are currently clinical available genotypic analysis assay . They have their own advantages and disadvantages in sensitivity, specificity, and application.…”

Section: Introductionmentioning

confidence: 99%

Developing a New qPCR‐Based System for Screening Mutation

Zhu

Zhao

Liu

et al. 2019

Small

View full text Add to dashboard Cite

An accurate genotyping analysis is one of the critical prerequisites for lung cancer targeted therapy. Here, a quantitative polymerase chain reaction (qPCR)‐based mutation detection system, mutation‐selected amplification‐specific system PCR (MASS‐PCR), is developed. The specific primers and probes used in MASS‐PCR exactly match with the mutant sequence that only allows mutant gene to emit the fluorescence peak. To determine the sensitivity of MASS‐PCR, 717 lung cancer specimens, 61 formalin‐fixed paraffin‐embedded (FFPE) tissues, and 656 fresh reaction tissues are collected and undergo mutation detection of lung cancer driver genes (EGFR, KRAS, BRAF, HER2, MET, ALK, and ROS1). These samples are divided into two groups. Mutations in Group I, which has 631 fresh reaction tissues, are analyzed by MASS‐PCR and the amplification refractory mutation system PCR (ARMS‐PCR). While group II samples, 25 fresh reaction tissues and 61 FFPE tissues, are screened through MASS‐PCR and next‐generation sequencing (NGS). All results are verified by direct sequencing. MASS‐PCR shows high consistency with ARMS‐PCR (kappa value > 0.733) and NGS (kappa value = 0.79) (P < 0.001). For the samples with inconsistent MASS‐PCR and ARMS‐PCR results, DS results more likely support the MASS‐PCR results. These data suggest that MASS‐PCR is a convenient, accurate, and economical method for the detection of lung cancer driver gene mutations in clinical practice.

show abstract

Section: Introductionmentioning

confidence: 99%

Developing a New qPCR‐Based System for Screening Mutation

Zhu

Zhao

Liu

et al. 2019

Small

View full text Add to dashboard Cite

show abstract

“…Even if new technologies are under development, the sensitivity is probably not high enough to substitute tissue-based NGS approaches. Novel applications in thoracic oncology will probably emerge [ 85 , 86 , 87 , 88 , 89 , 90 , 91 ]. Several areas of investigation have been made on analyses of other blood components such as circulating exosomes and microRNAs [ 92 , 93 , 94 ].…”

Section: Discussionmentioning

confidence: 99%

Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology

Hofman

2017

Cancers

View full text Add to dashboard Cite

The practice of liquid biopsy (LB) has revolutionized the care of patients with metastatic lung cancer. Many oncologists now use this approach in daily practice, applying precise procedures for the detection of activating or resistance mutations in EGFR. These tests are performed with plasma DNA and have been approved as companion diagnostic test for patients treated with tyrosine kinase inhibitors. ALK is another important target in lung cancer since it leads to treatment of patients who are positive for a rearrangement in ALK identified with tumor tissue. By analogy with EGFR, LB for detection of genomic alterations in ALK (rearrangements or mutations) has been rapidly adopted in the clinic. However, this promising approach has some limitations and has not yet been disseminated as much as the blood test targeting EGFR. In addition to these two therapeutic targets LB can be used for evaluation of the genomic status of other genes of interest of patients with lung cancer (ROS1, RET, NTRK MET, BRAF, HER2, etc.). LB can be performed to evaluate a specific target or for a more or less complex panel of genes. Considering the number of potential targets for clinical trials, techniques of next-generation sequencing of circulating DNA are on the rise. This review will provide an update on the contribution of LB to care of patients with metastatic lung cancer, including the present limits of this approach, and will consider certain perspectives.

show abstract

“…I agree that combined multimode statistics might enhance the accuracy of radiomics in assessment of lung cancer but further studies are needed to test this hypothesis, and additional refinements and improvements are also needed in image‐based radiomics. It is underlined that time is of the essence as minimally invasive liquid biopsies for circulating DNA and RNA biomarkers bring additional challenges to the role of chest CT and its associated radiomics in the field of lung cancer imaging …”

Section: Against the Proposition: Ge Wang Phdmentioning

confidence: 99%